Lysosomal integral membrane protein type-2 (LIMP-2/SCARB2) is a substrate of cathepsin-F, a cysteine protease mutated in type-B-Kufs-disease

Biochemical and Biophysical Research Communications

Volumn 457, Issue 3, 2015, Pages 334-340

  Peters, Judith ^a   Rittger, Andrea ^a   Weisner, Rebecca ^a   Knabbe, Johannes ^a   Zunke, Friederike ^a   Rothaug, Michelle ^a   Damme, Markus ^a   Berkovic, Samuel F ^b   Blanz, Judith ^a   Saftig, Paul ^a   Schwake, Michael ^c  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c BIELEFELD UNIVERSITY   (Germany)

Author keywords

Cathepsin F; Kufs disease; LIMP 2; Lysosomal storage disease; Neuronal ceroid lipofuscinosis

Indexed keywords

CATHEPSIN F; LYSOSOMAL INTEGRAL MEMBRANE PROTEIN TYPE 2; MEMBRANE PROTEIN; UNCLASSIFIED DRUG; CD36 ANTIGEN; CTSF PROTEIN, HUMAN; CTSF PROTEIN, MOUSE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN; MUTANT PROTEIN; RECOMBINANT PROTEIN; SCARB2 PROTEIN, HUMAN; SCARB2 PROTEIN, MOUSE; SCAVENGER RECEPTOR;

ANIMAL CELL; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; CONTROLLED STUDY; EMBRYO; GENE MUTATION; GENETIC ASSOCIATION; HETEROLOGOUS EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; LYSOSOME; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PURIFICATION; TYPE B KUFS DISEASE; WILD TYPE; ANIMAL; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; ENZYME SPECIFICITY; GENETICS; HEK293 CELL LINE; METABOLISM; MOUSE; NEURONAL CEROID LIPOFUSCINOSIS; PROTEIN CONFORMATION; PROTEIN SECONDARY STRUCTURE;

HUMAN ENTEROVIRUS 71;

ANIMALS; ANTIGENS, CD36; CATHEPSIN F; CELL LINE; HEK293 CELLS; HUMANS; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; LYSOSOMES; MICE; MODELS, MOLECULAR; MUTANT PROTEINS; NEURONAL CEROID-LIPOFUSCINOSES; PROTEIN CONFORMATION; PROTEIN STRUCTURE, SECONDARY; PROTEOLYSIS; RECEPTORS, SCAVENGER; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY;

EID: 84922703278     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.12.111     Document Type: Article

References (40)

1. D. Reczek, M. Schwake, J. Schroder, et al., LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase, Cell 131 (2007) 770-783.
2. D. Neculai, M. Schwake, M. Ravichandran, et al., Structure of LIMP-2 provides functional insights with implications for SR-BI and CD36, Nature 504 (2013) 172-176.
3. J. Blanz, J. Groth, C. Zachos, et al., Disease-causing mutations within the lysosomal integral membrane protein type 2 (LIMP-2) reveal the nature of binding to its ligand beta-glucocerebrosidase, Hum. Mol. Genet. 19 (2010) 563-572.
4. C. Zachos, J. Blanz, P. Saftig, et al., A critical histidine residue within LIMP-2 mediates pH sensitive binding to its ligand beta-glucocerebrosidase, Traffic 13 (2012) 1113-1123.
5. S. Yamayoshi, Y. Yamashita, J. Li, et al., Scavenger receptor B2 is a cellular receptor for enterovirus 71, Nat. Med. 15 (2009) 798-801.
6. S. Yamayoshi, S. Iizuka, T. Yamashita, et al., Human SCARB2-dependent infection by coxsackievirus A7, A14, and A16 and enterovirus 71, J. Virol. 86 (2012) 5686-5696.
7. T. Kuronita, E.L. Eskelinen, H. Fujita, et al., A role for the lysosomal membrane protein LGP85 in the biogenesis and maintenance of endosomal and lysosomal morphology, J. Cell. Sci. 115 (2002) 4117-4131.
8. S.F. Berkovic, L.M. Dibbens, A. Oshlack, et al., Array-based gene discovery with three unrelated subjects shows SCARB2/LIMP-2 deficiency causes myoclonus epilepsy and glomerulosclerosis, Am. J. Hum. Genet. 82 (2008) 673-684.
9. L.M. Dibbens, R. Michelucci, A. Gambardella, et al., SCARB2 mutations in progressive myoclonus epilepsy (PME) without renal failure, Ann. Neurol. 66 (2009) 532-536.
10. P. Steenhuis, J. Froemming, T. Reinheckel, et al., Proteolytic cleavage of the disease-related lysosomal membrane glycoprotein CLN7, Biochim. Biophys. Acta 1822 (2012) 1617-1628.
11. L.R. Savalas, B. Gasnier, M. Damme, et al., Disrupted in renal carcinoma 2 (DIRC2), a novel transporter of the lysosomal membrane, is proteolytically processed by cathepsin L, Biochem. J. 439 (2011) 113-128.
12. S. Durand, M. Feldhammer, E. Bonneil, et al., Analysis of the biogenesis of heparan sulfate acetyl-CoA:alpha-glucosaminide N-acetyltransferase provides insights into the mechanism underlying its complete deficiency in mucopolysaccharidosis IIIC, J. Biol. Chem. 285 (2010) 31233-31242.
13. I. Santamaria, G. Velasco, A.M. Pendas, et al., Molecular cloning and structural and functional characterization of human cathepsin F, a new cysteine proteinase of the papain family with a long propeptide domain, J. Biol. Chem. 274 (1999) 13800-13809.
14. B. Wang, G.P. Shi, P.M. Yao, et al., Human cathepsin F. Molecular cloning, functional expression, tissue localization, and enzymatic characterization, J. Biol. Chem. 273 (1998) 32000-32008.
15. G.P. Shi, R.A. Bryant, R. Riese, et al., Role for cathepsin F in invariant chain processing and major histocompatibility complex class II peptide loading by macrophages, J. Exp. Med. 191 (2000) 1177-1186.
16. K. Oorni, M. Sneck, D. Bromme, et al., Cysteine protease cathepsin F is expressed in human atherosclerotic lesions, is secreted by cultured macrophages, and modifies low density lipoprotein particles in vitro, J. Biol. Chem. 279 (2004) 34776-34784.
17. K.R. Smith, H.H. Dahl, L. Canafoglia, et al., Cathepsin F mutations cause type B Kufs disease, an adult-onset neuronal ceroid lipofuscinosis, Hum. Mol. Genet. 22 (2013) 1417-1423.
18. R. Di Fabio, F. Moro, L. Pestillo, et al., Pseudo-dominant inheritance of a novel CTSF mutation associated with type B Kufs disease, Neurology 83 (2014) 1769-1770.
19. A. Jalanko, T. Braulke, Neuronal ceroid lipofuscinoses, Biochim. Biophys. Acta 1793 (2009) 697-709.
20. D.K. Nagler, T. Sulea, R. Menard, Full-length cDNA of human cathepsin F predicts the presence of a cystatin domain at the N-terminus of the cysteine protease zymogen, Biochem. Biophys. Res. Commun. 257 (1999) 313-318.
21. A.C. Gamp, Y. Tanaka, R. Lullmann-Rauch, et al., LIMP-2/LGP85 deficiency causes ureteric pelvic junction obstruction, deafness and peripheral neuropathy in mice, Hum. Mol. Genet. 12 (2003) 631-646.
22. O. Schieweck, M. Damme, B. Schroder, et al., NCU-G1 is a highly glycosylated integral membrane protein of the lysosome, Biochem. J. 422 (2009) 83-90.
23. M. Rothaug, F. Zunke, J.R. Mazzulli, et al., LIMP-2 expression is critical for beta-glucocerebrosidase activity and alpha-synuclein clearance, Proc. Natl. Acad. Sci. U S A 111 (2014) 15573-15578.
24. H. Umezawa, Structures and activities of protease inhibitors of microbial origin, Meth. Enzymol. 45 (1976) 678-695.
25. M. Tamai, C. Yokoo, M. Murata, et al., Efficient synthetic method for ethyl (+)-(2S,3S)-3-[(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl]-2-oxiranecarb oxylate (EST), a new inhibitor of cysteine proteinases, Chem. Pharm. Bull. (Tokyo) 35 (1987) 1098-1104.
26. T. Wex, B. Levy, H. Wex, et al., Human cathepsins F and W: a new subgroup of cathepsins, Biochem. Biophys. Res. Commun. 259 (1999) 401-407.
27. T. Yoshimori, A. Yamamoto, Y. Moriyama, et al., Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells, J. Biol. Chem. 266 (1991) 17707-17712.
28. T. Braulke, H.J. Geuze, J.W. Slot, et al., On the effects of weak bases and monensin on sorting and processing of lysosomal enzymes in human cells, Eur. J. Cell. Biol. 43 (1987) 316-321.
29. J.G. Barriocanal, J.S. Bonifacino, L. Yuan, et al., Biosynthesis, glycosylation, movement through the Golgi system, and transport to lysosomes by an N-linked carbohydrate-independent mechanism of three lysosomal integral membrane proteins, J. Biol. Chem. 261 (1986) 16755-16763.
30. N. Andrejewski, E.L. Punnonen, G. Guhde, et al., Normal lysosomal morphology and function in LAMP-1-deficient mice, J. Biol. Chem. 274 (1999) 12692-12701.
31. S. Wilke, J. Krausze, K. Bussow, Crystal structure of the conserved domain of the DC lysosomal associated membrane protein: implications for the lysosomal glycocalyx, BMC Biol. 10 (2012) 62.
32. M. Dang, X. Wang, Q. Wang, et al., Molecular mechanism of SCARB2-mediated attachment and uncoating of EV71, Protein Cell. 5 (2014) 692-703.
33. Y. Zhao, J. Ren, S. Padilla-Parra, et al., Lysosome sorting of beta-glucocerebrosidase by LIMP-2 is targeted by the mannose 6-phosphate receptor, Nat. Commun. 5 (2014) 4321.
34. T. Wex, B. Levy, H. Wex, et al., Human cathepsins W and F form a new subgroup of cathepsins that is evolutionary separated from the cathepsin B- and L-like cysteine proteases, Adv. Exp. Med. Biol. 477 (2000) 271-280.
35. S.F. Berkovic, S. Carpenter, F. Andermann, et al., Kufs' disease: a critical reappraisal, Brain 111 (Pt 1) (1988) 27-62.
36. T. Arsov, K.R. Smith, J. Damiano, et al., Kufs disease, the major adult form of neuronal ceroid lipofuscinosis, caused by mutations in CLN6, Am. J. Hum. Genet. 88 (2011) 566-573.
37. C.H. Tang, J.W. Lee, M.G. Galvez, et al., Murine cathepsin F deficiency causes neuronal lipofuscinosis and late-onset neurological disease, Mol. Cell. Biol. 26 (2006) 2309-2316.
38. M. Koike, H. Nakanishi, P. Saftig, et al., Cathepsin D deficiency induces lysosomal storage with ceroid lipofuscin in mouse CNS neurons, J. Neurosci. 20 (2000) 6898-6906.
39. U. Felbor, B. Kessler, W. Mothes, et al., Neuronal loss and brain atrophy in mice lacking cathepsins B and L, Proc. Natl. Acad. Sci. U S A 99 (2002) 7883-7888.
40. A.P. Lieberman, R. Puertollano, N. Raben, et al., Autophagy in lysosomal storage disorders, Autophagy 8 (2012) 719-730.